PCR Molecular Diagnostics Market Research Report 2021 - Global Growth, Trends, COVID-19 Impact, and Forecasts to 2026 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "PCR Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

The PCR Molecular Diagnostics market is expected to grow with an estimated CAGR of 3.5%, over the forecast period.

PCR are most widely used diagnostic tests for detecting pathogens, including viruses. It Is considered as one of the best tests to identify the COVID 19 virus in the human body.

Rising technological advancement and growing public awareness of preventive care are propelling the market growth. Though COVID 19 has a major impact on the medical industry, the PCR Molecular Diagnostics market is on a positive trend.

The rising prevalence of cancer and infectious diseases is also a major factor that drives PCR molecular diagnostics market. The Infectious Diseases Society of America has stated that every year there is a probability of new, potentially dangerous bacteria, viruses, fungi such as severe acute respiratory syndrome (SARS).

World Health Organization in March 2020 stated that more than 17% of all infectious diseases are vector born. In addition to this the Global Cancer facts and figures, 4th edition, published at American Cancer Society reported that according to International Agency for Research on Cancer (IARC), the cancer cases are rising and it is expected to reach 27.5 million by 2040, aging is also a supporting factor for the rise in new cancer's.

Adoption and implementation of software associated to molecular diagnostics at respective diagnostics centers is expected to boost the market growth. Additionally PCR molecular diagnostics also played a crucial role in cancer diseases. For instance, in March 2020, a review made on Important Diagnostic Methods of Cancer Biomarkers related Diagnosis and Treatment reported that Polymerase chain reaction (PCR) & Real Time PCR plays a vital role in cancer diagnostics.

Furthermore, in June 2020, Mobidiag Ltd., announced that it has received CE-IVD markings for its Novodiag COVID-19 and Amplidiag COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19).

Based on well-established high-throughput qualitative PCR technology, 48 samples can be processed in less than three hours while running on Mobidiag's Amplidiag Easy platform. Hence, owing to above mentioned factors, the market is expected to witness significant growth in the future.

Competitive Landscape

The PCR Molecular Diagnostics market is moderately competitive with several players across the globe. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of infectious and cancer diseases, especially the COVID 19, many regional players are expected to grow their presence in the market.

Some of the major players of the market are Abbott Laboratories, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Takara Bio, Inc., Qiagen N.V.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Prevalence of Cancer and Infectious Diseases

4.2.2 Technological Advancements in PCR Devices

4.2.3 Increasing Demand For Rapid Diagnostic Tests And Growing Adoption of PCR

4.3 Market Restraints

4.3.1 High Cost of PCR Instrument/Devices

4.3.2 Stringent Regulatory Policies

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Product

5.1.1 Instrument

5.1.1.1 Standard PCR Systems

5.1.1.2 Digital PCR Systems

5.1.1.3 Real-time PCR Systems

5.1.2 Reagents and Consumables

5.1.3 Software

5.2 By Application

5.2.1 Infectious Disease Testing

5.2.2 Oncology Testing

5.2.3 Other Applications

5.3 By End User

5.3.1 Hospitals

5.3.2 Diagnostic Laboratories

5.3.3 Others

5.4 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Abbott Laboratories

6.1.2 Thermo Fisher Scientific, Inc.

6.1.3 Bio-Rad Laboratories, Inc.

6.1.4 Takara Bio, Inc.

6.1.5 Qiagen N.V.

6.1.6 Danaher Corporation

6.1.7 Becton Dickinson and Company

6.1.8 Agilent Technologies, Inc.

6.1.9 Eppendorf AG

6.1.10 F. Hoffman-La Roche Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/swq6sd